Open Label Study of Adalimumab in Subjects Who Have a Sub-Optimal Response to Systemic Therapy or Phototherapy.

Trial Profile

Open Label Study of Adalimumab in Subjects Who Have a Sub-Optimal Response to Systemic Therapy or Phototherapy.

Completed
Phase of Trial: Phase III

Latest Information Update: 20 Mar 2012

At a glance

  • Drugs Adalimumab (Primary)
  • Indications Psoriasis
  • Focus Therapeutic Use
  • Sponsors Abbott Laboratories
  • Most Recent Events

    • 20 Mar 2012 Results of an indirect comparison economic comparison of the ACCORD and M10-238 studies presented at the 70th Annual Meeting of the American Academy of Dermatology.
    • 27 May 2010 Actual number of patients added to 152 as reported by ClinicalTrials.gov.
    • 03 Oct 2009 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top